Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies

Carmelo Gurnari, Simona Pagliuca, Lisa Durkin, Laila Terkawi, Hassan Awada, Sunisa Kongkiatkamon, Misam Zawit, Eric D. Hsi, Hetty E. Carraway, Heesun J. Rogers, Valeria Visconte, Jaroslaw P. Maciejewski

Blood (2021) 137 (26): 3685–3689.

https://doi.org/10.1182/blood.2021010811

Published: 2021

Includes: Supplemental data

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

https://doi.org/10.1182/blood-2019-129131

Published: 2019

Journal Articles

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Neetha Parameswaran, PhD, Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Lisa Durkin, Yvonne Parker, Daniel Lindner, MD PhD, Eric D. Hsi, MD, Deepa Jagadeesh, MDMPH

Blood (2019) 134 (Supplement_1): 1515.

https://doi.org/10.1182/blood-2019-131800

Published: 2019

Journal Articles

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells

Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Ruoying Chen, PhD, Lisa Durkin, Andrew J. Souers, PhD, Darren C. Phillips, PhD, Eric D. Hsi, MD

Blood (2016) 128 (22): 1593.

https://doi.org/10.1182/blood.V128.22.1593.1593

Published: 2016

Journal Articles

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Xiaoxian Zhao, PhD, Darren C. Phillips, PhD, Andrew J. Souers, PhD, Juraj Bodo, PhD, Paul Tapang, Daniel H Albert, PhD, Lisa Durkin, Eric D. Hsi, MD

Blood (2015) 126 (23): 2746.

https://doi.org/10.1182/blood.V126.23.2746.2746

Published: 2015

Journal Articles

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

Quteba Ebrahem, Reda Z. Mahfouz, MDPhD, Lisa Durkin, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD, Betty K. Hamilton, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Frederic J. Reu, MD, Eric D. Hsi, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2015) 126 (23): 678.

https://doi.org/10.1182/blood.V126.23.678.678

Published: 2015

Journal Articles

CCMCL1: a new model of aggressive mantle cell lymphoma

Xiaoxian Zhao, Selina Chen-Kiang, Shashirekha Shetty, Maurizio Di Liberto, Juraj Bodo, Lisa Durkin, Ken Eng, Olivier Elemento, Mitchell R. Smith, Eric D. Hsi

Blood (2015) 125 (17): 2730–2732.

https://doi.org/10.1182/blood-2015-01-622795

Published: 2015

Includes: Supplemental data

Journal Articles

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Danyu Sun, MD, PhD, Jeffrey J. Lin, PhD, Lisa Durkin, Shashirekha Shetty, PhD, Mitchell R. Smith, MD, PhD, Eric D. Hsi, MD

Blood (2013) 122 (21): 645.

https://doi.org/10.1182/blood.V122.21.645.645

Published: 2013

Journal Articles

Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics

Reda Z Mahfouz, MD/PhD, Englehaupt Rickki, Joyce A Juersivich, Kathleen Cooper, RN, MSc, Lisa Durkin, Tomas Radivoyevitch, PhD, Ramon V. Tiu, MD, BS, Frederic J. Reu, MD, Robert M Dean, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Anjali Advani, MD, Eric D. Hsi, MD, Mikkael A Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Yogenthiran Saunthararajah, MD

Blood (2012) 120 (21): 1696.

https://doi.org/10.1182/blood.V120.21.1696.1696

Published: 2012

Journal Articles

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

Blood (2012) 120 (15): 3048–3057.

https://doi.org/10.1182/blood-2012-06-435297

Published: 2012

Includes: Supplemental data

Journal Articles

A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine,

Yogen Saunthararajah, MD, Reda Z Mahfouz, MD, Ricki Englehaupt, Joy Juersivich, RN, MSc, Lisa Durkin, Tomas Radivoyevitch, PhD, Kathleen Cooper, RN, MSc, Manual Afable, MD, Robert Dean, Anjali S. Advani, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward A. Copelan, MD, Eric D. Hsi, MD, Jaroslaw P. Maciejewski, MD, PhD, Mikkael A Sekeres, MD

Blood (2011) 118 (21): 3830.

https://doi.org/10.1182/blood.V118.21.3830.3830

Published: 2011

Journal Articles

CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma

Xiaoxian Zhao, PhD., Suzanne Ybarra, Lisa Durkin, Mien Sho, Neeraj Kumar, Brian Gordon, Paul Algate, Gary Starling, PhD, Debra Chao, Ph.D., Eric Hsi, MD

Blood (2010) 116 (21): 3098.

https://doi.org/10.1182/blood.V116.21.3098.3098

Published: 2010

NARROW

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

CCMCL1: a new model of aggressive mantle cell lymphoma

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine,

CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only